Format

Send to

Choose Destination
Arch Neurol. 2012 Oct;69(10):1259-69.

Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.

Collaborators (170)

Calandra T, DiMarco J, Easton JD, Hudson LD, Kesselring J, Laupacis A, Temkin N, Weinshenker BG, Zarbin M, Calabresi P, Hohlfeld R, Kappos L, O'Connor P, Polman C, Beran R, Paine M, MacDonell R, Heard R, Boundy K, Van Opdenbosch L, Bartholomé E, Pandololfo M, Seeldrayers P, Dubois B, Vande Gaer L, Decoo D, Mulleners E, Bhan V, Brunet D, Kremenchutzky M, Selchen DH, Lachapelle J, Christie S, Veloso F, Devonshire V, Rektor I, Ondrich V, Kanovsky P, Zapletalová O, Ambler Z, Ehler E, Meluzinova E, Havrdová E, Pazdera L, Vysata O, Vachova M, Gross-Paju K, Kallela M, Kinnunen E, Sumelahti ML, Eralinna JP, Airas L, Clavelou P, Moreau T, Vermersch P, Pelletier J, Camu W, Damier P, Wiertlewski S, Labauge P, Gout O, Lubetzki C, Edan G, De Seze J, Menck S, Haas J, Einhäupl M, Harms L, Wandinger KP, Zipp F, Kieseier B, Anders D, Berghoff M, Oschmann P, Rosenkranz T, Heesen C, Bergh FT, Sailer M, Hohlfeld R, Bischoff F, Marziniak M, Muller M, Kleiter I, Steinbrecher A, Kowalik A, Melms A, Weissert R, Wiendl H, Karageorgiou C, Fakas N, Maltezou M, Mitsikostas D, Káposzta Z, Rozsa C, Valikovics A, Kerényi L, Hutchinson M, Milo R, Miller A, Shahien R, Achiron A, Polman C, Frequin S, Jongen P, Zwanikken C, Hintzen R, Anten B, Hupperts R, Visser L, Kochanowicz J, Drozdowski W, Fryze W, Wajgt A, Selmaj K, Kozubski W, Dorobek M, Pniewski J, Czlonkowska A, Kwiecinski H, Stepien A, Panea C, Boeru G, Perju-Dumbrava L, Zaharia C, Popescu CD, Balasa R, Bejenaru O, Yakupov EZ, Yakhhno N, Kotov S, Shmyrev V, Zavalishin I, Elchaninov AP, Stolyarov I, Odinak M, Turcani P, Kurča E, Vyletĕlka J, Heckman J, Isaacs M, Coetzee C, Lycke J, Hillert J, Olsson T, Kappos L, Gugleta K, Sturzenegger R, Schluep M, Goebels N, Linnebank M, Irkec C, Karabudak R, Turan OF, Neyal M, Işik N, Sutlas PN, Akman-Demir G, Siva A, Idiman E, Kocaman A, Zorlu Y, Sevim S, Cottrell D, Silber E, Barnes D, Bates D, Constantinescu C, Sharrack B, Bendfeldt K, Radue EW.

Author information

1
Medical Image Analysis Center, University Hospital, Basel, Switzerland. eradue@uhbs.ch

Abstract

OBJECTIVE:

To assess the impact of fingolimod (FTY720) therapy on magnetic resonance imaging measures of inflammatory activity and tissue damage in patients participating in a 2-year, placebo-controlled, phase 3 study.

DESIGN:

Patients with active relapsing-remitting multiple sclerosis were randomized to receive fingolimod, 0.5 mg; fingolimod, 1.25 mg; or placebo for 2 years. Standardized magnetic resonance imaging scans were obtained at months 0, 6, 12, and 24 and centrally evaluated for number and volume of T1 gadolinium-enhancing, T2 hyperintense, and T1 hypointense lesions and for percentage of brain volume change. Findings were compared across subgroups by treatment and baseline characteristics.

SETTING:

Worldwide, multicenter clinical trial.

PATIENTS:

Patients were part of the fingolimod FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) clinical trial for relapsing-remitting multiple sclerosis (N=1272).

MAIN OUTCOME MEASURES:

We measured the effect of therapy on acute inflammatory activity, burden of disease, and irreversible loss of brain volume.

RESULTS:

Fingolimod therapy resulted in rapid and sustained reductions in inflammatory lesion activity as assessed by gadolinium-enhancing and new/newly enlarged T2 lesions after 6, 12, and 24 months of therapy (P.001, all comparisons vs placebo). Changes in T2 hyperintense and T1 hypointense lesion volume also significantly favored fingolimod (P.05, all comparisons). Fingolimod, 0.5 mg (licensed dose), significantly reduced brain volume loss during months 0 to 6, 0 to 12, 12 to 24, and 0 to 24 (P.05, all comparisons) vs placebo, and subgroup analyses confirmed these effects over 2 years irrespective of the presence/absence of gadolinium-enhancing lesions, T2 lesion load, previous treatment status, or level of disability.

CONCLUSION:

These results, coupled with the significant reductions in relapse rates and disability progression reported previously, support the positive impact on long-term disease evolution.

TRIAL REGISTRATION:

clinicaltrials.gov Identifier: NCT00289978

PMID:
22751847
DOI:
10.1001/archneurol.2012.1051
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center